Free Trial

Akoya Biosciences Q4 2023 Earnings Report

Akoya Biosciences logo
$2.49 -0.06 (-2.35%)
(As of 12/20/2024 05:15 PM ET)

Akoya Biosciences EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.50

Akoya Biosciences Revenue Results

Actual Revenue
$26.49 million
Expected Revenue
$26.12 million
Beat/Miss
Beat by +$370.00 thousand
YoY Revenue Growth
N/A

Akoya Biosciences Announcement Details

Quarter
Q4 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Akoya Biosciences Earnings Headlines

Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Update
Akoya Biosciences, NeraCare enter exclusive global license agreement
This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Akoya Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email.

About Akoya Biosciences

Akoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

View Akoya Biosciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings